{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030299","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.513508+00:00","generated_at":"2026-05-30T22:58:57.654883+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"CervoMed to present neflamapimod biomarker and baseline data at CTAD; topline RewinD-LB due Dec 2024","bullets":["Two late-breaking oral presentations at CTAD in Madrid (Oct 29 – Nov 1) on neflamapimod for DLB.","Plasma biomarker data from AscenD-LB Phase 2a study will be presented November 1.","Baseline data from RewinD-LB Phase 2b study to be featured; CEO says increases confidence in positive outcome.","Topline data from RewinD-LB Phase 2b study expected in December 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030299","json":"https://secwatch.observer/filing/0001437749-24-030299.json","markdown":"https://secwatch.observer/filing/0001437749-24-030299.md","text":"https://secwatch.observer/filing/0001437749-24-030299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924030299/0001437749-24-030299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924030299/crvo20240930_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T22:58:57.654883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}